JHM Biopharmaceutical (Hangzhou) Co., Ltd. (“JHM”) today announced the enrollment of its first patient in a clinical trial of its innovative, patented Recombinant Type A Botulinum Toxin. The trial, led by Huashan Hospital (affiliated to Fudan University), marks the official launch of neurological research in China using this treatment for adult stroke patients who suffer from upper limb spasticity.